Zynerba Pharmaceuticals, Inc. (ZYNE) PT Set at $15.00 by Roth Capital
A number of other brokerages have also recently issued reports on ZYNE. Maxim Group set a $32.00 price objective on shares of Zynerba Pharmaceuticals and gave the company a buy rating in a research note on Monday, June 26th. Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, July 13th. BidaskClub upgraded shares of Zynerba Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, July 12th. Cantor Fitzgerald set a $28.00 price target on shares of Zynerba Pharmaceuticals and gave the company a buy rating in a report on Thursday, June 8th. Finally, Jefferies Group LLC reiterated a buy rating and set a $32.00 price target on shares of Zynerba Pharmaceuticals in a report on Sunday, July 9th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $14.63.
Zynerba Pharmaceuticals (ZYNE) opened at 10.02 on Friday. Zynerba Pharmaceuticals has a 52 week low of $5.80 and a 52 week high of $23.57. The company’s market cap is $132.84 million. The company’s 50-day moving average is $7.07 and its 200-day moving average is $7.07.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its quarterly earnings data on Tuesday, August 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.04). On average, analysts anticipate that Zynerba Pharmaceuticals will post ($2.42) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/05/zynerba-pharmaceuticals-inc-zyne-pt-set-at-15-00-by-roth-capital.html.
A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Zynerba Pharmaceuticals by 12.4% during the 2nd quarter. Vanguard Group Inc. now owns 478,763 shares of the company’s stock valued at $8,125,000 after buying an additional 52,952 shares during the last quarter. Marshall Wace North America L.P. bought a new position in Zynerba Pharmaceuticals in the 1st quarter worth $9,362,000. JPMorgan Chase & Co. raised its holdings in Zynerba Pharmaceuticals by 65,190.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 326,450 shares of the company’s stock worth $5,539,000 after purchasing an additional 325,950 shares in the last quarter. Citigroup Inc. raised its holdings in Zynerba Pharmaceuticals by 13,501.1% in the 2nd quarter. Citigroup Inc. now owns 221,698 shares of the company’s stock worth $3,762,000 after purchasing an additional 220,068 shares in the last quarter. Finally, State Street Corp bought a new position in Zynerba Pharmaceuticals in the 2nd quarter worth $2,698,000. Institutional investors own 34.32% of the company’s stock.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Receive News & Stock Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.